Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Impact · against what's priced in

The article provides limited catalyst potential for Eli Lilly as its core growth drivers—the oral GLP-1 launch and the pipeline—are already factored into the valuation. Novo Nordisk faces slight headwinds from Eli Lilly's competitive entry into the weekly insulin market, though this competition is expected.

LLY+0.00: Already priced in
The price assumes: Current GLP-1 market dominance and the initial U.S. launch of the oral pill Foundayo

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

What matters in this story

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

What matters in this story

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

How each ticker is affected

Connected tickers

Track these names every morning.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

Dow rises 556 points as investors rotate out of AI stocks on inflation fears

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

What matters in this story

Next reads from the same story arc

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

What matters in this story

Next reads from the same story arc

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

How each ticker is affected

Connected tickers

Track these names every morning.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

Dow rises 556 points as investors rotate out of AI stocks on inflation fears